Marksans Pharma Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/z7eo5gxs0ewkqw0093r42g8c.pdf

Key Takeaways


Revenue Growth & Geographic Mix

Mark Saldanha: "But I do believe INR3,000 crores is just a tip of the iceberg and we have a lot of potential of growth based on our strategy that we are executing as on today."

Margin Performance & Cost Headwinds

Mark Saldanha: "But because there is no clarity, we would like to wait and watch because if tomorrow, things do correct, the overall market will correct dramatically. And the last thing we need is to press a panic today because we are sitting on inventory of a lot of products."

Teva Facility & Capacity

Mark Saldanha: "We still have a potential of maybe 40% to 50% of growth coming from there and we are working towards that."

Pipeline & R&D


M&A & Capital Allocation

Mark Saldanha: "But for us, we've been always very conservative to make sure that whatever we acquire is value, basically return on investment and creates value for the shareholders. So we are very conservative in the valuation. We don't go for some high-ticket deals and throw money at it."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetINR4,000 croresNext 2 years
Revenue doublingDouble revenue from current levelsNext 3 to 5 years
FY27 top-line growth15% to 20% (conservative)FY27
FY27 EBITDA marginIn the range of 20% to 21%FY27
Australia milestoneReach $100 million in revenueWithin 3 years
UK product filingsFile over 200 productsNext 4 years
Teva facility growth40% to 50% growth potential from the facilityUndated (working toward it)
M&A transactionAt least one deal closed2027 (optimistic)
Europe revenue contributionSome results from Europe entrySecond half of FY27
Canada revenue contributionSmall revenue to trickle inLatter part of FY27
R&D spendingMaintain at 3% of revenueOngoing

Key Metrics

MetricQ4 FY26
Operating revenue₹856 cr, +20.8% YoY
North America revenue₹406 cr, +23.6% YoY
UK and EU formulation revenue₹308 cr, +12.3% YoY, highest ever quarterly revenue
Australia and New Zealand revenue₹123 cr, +61.3% YoY
Rest of world revenue₹19 cr
Gross profit₹465 cr, +21.5% YoY
Gross margin54.4%, expansion of 27 bps YoY
EBITDA₹195 cr, +54% YoY
EBITDA margin22.8%, expanded 491 bps YoY
Profit after tax₹149 cr, +64.3% YoY
EPS₹3.3
FY26 operating revenue₹2,951 cr, +12.5% YoY
FY26 gross margin56.7%, expanded 32 bps YoY
FY26 EBITDA margin20.4%
FY26 PAT₹420 cr
FY26 EPS₹9.2
FY26 free cash flow₹328 cr
Working capital138 days
R&D spend₹89 cr in FY26, 3% of consolidated revenue
Cash and cash equivalents₹990 cr as of March 31, 2026
Dividend₹0.90 per equity share, 90% payout on face value for FY26
North America FY26 revenue₹1,533 cr, +24% YoY, 52% of total operating revenue
UK and EU FY26 revenue₹1,015 cr, 34.4% of total operating revenue
Australia and New Zealand FY26 revenue₹303 cr, 10.3% of total operating revenue
North America SKUs launched in FY26112 SKUs, 51 additional products in pipeline
UK product pipeline18 new approvals, 30 under review, 24 awaiting approvals; over 200 filings planned over next 4 years
Australia branded generic launches11 branded generic products launched through Nova Pharma
Teva facility utilizationVery close to 50% of capacity
Total operational capacity utilization50% to 55% across all 3 facilities, 1,300 cr to 1,400 cr units
Raw material price escalationOver 20% to 30% on petroleum-related raw materials
Logistics cost impactAround 2%
FY27 revenue growth guidance15% to 20% conservatively
FY27 EBITDA margin guidance20% to 21%, same range
Revenue target₹4,000 cr in the next 2 years
Australia and New Zealand revenue target$100 million, currently at halfway mark
Marksans stake in Australia and New Zealand entity60%